Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer

Between 2011 and 2022, assay use resulted in a 58% reduction in chemotherapy administration and net savings of over €3.3 million.

Authors

Bryan T. Hennessy (ORCID: https://orcid.org/0000-0002-7871-6477)
Roisín M. Connolly (ORCID: https://orcid.org/0000-0003-0056-1070)
Ciara O’Hanlon-Brown
Séamus O’Reilly (ORCID: https://orcid.org/0000-0002-2887-7336)
Cecily Quinn (ORCID: https://orcid.org/0000-0001-8920-5480)
Michaela J. Higgins (ORCID: https://orcid.org/0000-0002-9065-8652)
Ciara Murray (ORCID: https://orcid.org/0000-0003-3564-5696)
Catherine Weadick (ORCID: https://orcid.org/0000-0003-4823-7392)
Damian McCartan (ORCID: https://orcid.org/0000-0002-2488-095X)
John Paul Crown (ORCID: https://orcid.org/0000-0002-3125-7613)
Robert A. McLaughlin (ORCID: https://orcid.org/0000-0001-6947-5061)
Sinéad Noonan (ORCID: https://orcid.org/0000-0002-7752-3876)
J.M. Walshe (ORCID: https://orcid.org/0000-0001-5458-4935)
Lynda McSorley (ORCID: https://orcid.org/0000-0002-3076-797X)
Danial Hadi (ORCID: https://orcid.org/0000-0002-1050-614X)
Patrick G. Morris (ORCID: https://orcid.org/0000-0002-6055-5273)
Catherine M. Kelly (ORCID: https://orcid.org/0000-0001-8355-6714)
Deirdre O’Mahony (ORCID: https://orcid.org/0000-0001-6987-445X)
Steven J. Millen
Iseult Browne (ORCID: https://orcid.org/0009-0005-7193-987X)
S O’Sullivan (ORCID: https://orcid.org/0000-0002-6043-5917)
A Hill (ORCID: https://orcid.org/0009-0004-9538-7144)
R S Prichard

Institutions

University College Dublin (IE)
Royal College of Surgeons in Ireland (IE)
University College Cork (IE)
Bon Secours Hospital Cork (IE)
Beaumont Hospital (IE)
Cork University Hospital (IE)
Mater Misericordiae University Hospital (IE)
Cancer Trials Ireland (IE)
St. Vincent's University Hospital (IE)
St. James's Hospital (IE)

Publication Details

Journal: Breast Cancer Research and Treatment
Published: 2024-10-04
DOI: https://doi.org/10.1007/s10549-024-07486-5
Citations: 2
Primary Topic: Breast Cancer Treatment Studies
Type: article
Field-Weighted Citation Impact: 0.57

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer

Bryan T. Hennessy, Roisín M. Connolly, Ciara O’Hanlon-Brown, Séamus O’Reilly, Cecily Quinn, Michaela J. Higgins, Ciara Murray, Catherine Weadick, Damian McCartan, John Paul Crown, Robert A. McLaughlin, Sinéad Noonan, J.M. Walshe, Lynda McSorley, Danial Hadi, Patrick G. Morris, Catherine M. Kelly, Deirdre O’Mahony, Steven J. Millen, Iseult Browne, S O’Sullivan, A Hill, R S Prichard

October 4, 2024article en

2 citations

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer

Authors

Institutions

Publication Details

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer

Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.